All In Biotech

Drug Trial Radar · NCT04221451

A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

75

Actual

Start

Jun 29, 2020

Primary completion

Dec 26, 2024

Study completion Dec 26, 2024

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jan 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objectives: Primary population (adult participants with late-onset GM2 gangliosidosis): To assess the efficacy and pharmacodynamics (PD) of daily oral dosing of venglustat when administered over a 104-week period Secondary population (participants with juvenile/adolescent late-onset GM2 gangliosidosis, GM1 gangliosidosis, saposin C deficiency, sialidosis type 1 or juvenile/adult galactosialidosis): To assess PD response (plasma and CSF GL-1 biomarker and disease specific biomarkers) of venglustat when administered once daily over a 104-week period Secondary Objectives: Primary population: * To assess the PD of daily oral dosing of venglustat and the effect of venglustat on selected performance test and scale over a 104-week period * To determine the safety and tolerability of venglustat when administered orally once daily over a 104-week period * To assess the pharmacokinetics (PK) of venglustat in plasma and cerebrospinal fluid (CSF) Secondary population: * To assess the effect of venglustat on selected performance tests and scale over a 104-week period * To determine the safety and tolerability of venglustat when administered once daily over a 104-week period * To assess the PK of venglustat in plasma and CSF * To assess the acceptability and palatability of the venglustat tablet

Conditions

  • Tay-Sachs Disease
  • Sandhoff Disease

Interventions

  • venglustat GZ402671Drug

    Pharmaceutical form: tablet Route of administration: oral

  • placeboDrug

    Pharmaceutical form: tablet Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PAP: PP: Percent Change From Baseline in CSF GM2 Biomarker to Week 104Time frame: Baseline (Day 1) and Week 104
  2. PAP: PP: Annualized Rate of Change From Baseline in the 9-HPT to Week 104Time frame: Baseline (Day 1) and Week 104
  3. PAP: SP: Percent Change From Baseline in Plasma and CSF Biomarkers (Glucosylceramide [GL-1] and GM2) to Week 104 in Juvenile/Adolescent Late-onset GM2 Gangliosidosis ParticipantsTime frame: Baseline (Day 1) and Week 104
  4. PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1 and GM1 Biomarkers to Week 104 in GM1 Gangliosidosis ParticipantsTime frame: Baseline (Day 1) and Week 104
  5. PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM2 and Monosialodihexosylganglioside (GM3) Biomarkers to Week 104 in Sialidosis Type 1 ParticipantTime frame: Baseline (Day 1) and Week 104
  6. PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM1 and GM3 Biomarkers to Week 104 in Juvenile/Adult Galactosialidosis ParticipantsTime frame: Baseline (Day 1) and Week 104
  7. PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1 Biomarker to Week 104 in Saposin C Deficiency ParticipantsTime frame: Baseline (Day 1) to Week 104

Locations

23 sites in 13 countries. Site status is shown where the registry gives one.

  • Ataxia Center and HD Center of Excellence, 300 UCLA Med Plaza, Suite B200 - Investigational site number 8400004

    Los Angeles, California

  • Emory Genetics - Investigational site number 8400006

    Atlanta, Georgia

  • NIH National Human Genome Research Institute - 10 Center Dr - Bldg. 10 CRC3-2551 MSC 1205 - Investigational site number 8400005

    Bethesda, Maryland

  • Massachusetts General Hospital - Charles River Plaza 175 Cambridge St. Ste 340 - Investigational site number 8400002

    Boston, Massachusetts

  • NYU Langone - 550 First Avenue-Investigational site number 8400001

    New York, New York

  • Clínica Universitaria Reina Fabiola Córdoba_investigational site number 0320001

    Córdoba, Argentina

  • Hospital Universitario Austral Pilar, Buenos Aires_Unidad de Investigación Clínica_investigational site number 0320002

    Pilar, Buenos Aires, Argentina

  • Hospital de Clinicas de Porto Alegre _investigational site number 0760001

    Porto Alegre, Rio Grande do Sul, Brazil

  • Vseobecna Fakultni Nemocnice V Praze Metabolicke centrum U Nemocnice 2_investigational site number 2030001

    Prague, Czechia

  • APHP - Centre Hospitalier la Pitié Salpetrière, Service de Neurologie, 47-83 Boulevard De l'Hôpital_Investigational site number 2500001

    Paris, France

  • Universitätsklinikum der Justus-Liebig-Universität Gießen Zentrum für Kinderheilkunde und Jugendmedizin Feulgenstraße 10-12_investigational site number 2760001

    Giessen, Germany

  • Investigational Site Number : 3800001

    Milan, Italy

  • Japanese Red Cross Akita Hospital 222-1 Nawashirosawa, Kamikitatesaruta_investigational site number 3920001

    Akita, Akita, Japan

  • Tohoku Medical and Pharmaceutical University Hospital_investigation site number 3920002

    Sendai, Miyagi, Japan

  • Centro Hospitalar Universitário Lisboa Norte- Hospital Santa Maria Avenida Professor Egas Moniz_investigational site number 6200002

    Lisbon, Portugal

  • Research Center Of Neurology 80, Volokolamskoye shosse_investigational site number 6430001

    Moscow, Russia

  • Hospital Universitari de Bellvitge. Feixa Llarga, S / N_investigational site number 7240004

    L'Hospitalet de Llobregat, Barcelona [Barcelona], Spain

  • Hospital Maternoinfantil Sant Joan de Déu Paseo de Sant Joan de Déu, 2_investigational site number 7240001

    Esplugues de Llobregat, Catalunya [Cataluña], Spain

  • Hospital Clínico Universitario de Santiago-CHUS. Travesia de Chopuana, s/n_investigational site number 7240002

    Santiago de Compostela, Galicia [Galicia], Spain

  • Gazi Universitesi Tip Fakultesi Emniyet Street Mevlana Blv Besevler Yenimahalle_investigational site number 7920001

    Ankara, Turkey (Türkiye)

  • Investigational Site Number : 8260003

    Manchester, United Kingdom

  • Salford Royal NHS Foundation Trust Salford Royal Hospital Stott Lane_investigational site number 8260002

    Salford, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust Addenbrookes Hospital Hills Road_investigational site number 8260001

    Cambridge, Cambridgeshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.